Technological Considerations and Test Selection

Dr. Roschewski addresses test heterogeneity, noting significant technological development over the past decade with continued advancement expected. He uses computer evolution analogies, comparing 1980s computers to current smartphones to illustrate potential improvement trajectories. Without clear guidelines, clinicians must independently decide between available options rather than avoiding testing entirely, which may not serve optimal patient care.

Dr. Melody discusses assay considerations across different lymphoma subtypes, particularly noting challenges in Hodgkin lymphoma due to limited cancer cells in tissue samples. Tumor-informed assays require tissue sequencing before blood detection, proving difficult when cancer cell numbers are minimal. Research-stage phased variant assays show effectiveness for Hodgkin lymphoma by detecting multiple somatic mutations on single DNA molecules, providing superior sensitivity and specificity compared to single nucleotide variant approaches.

For lymphomas with adequate tissue sampling, whole-genome sequencing targeting single-nucleotide variants appears effective for diffuse large B-cell lymphoma and follicular lymphoma, though less successful for Hodgkin lymphoma applications. Technology direction trends toward phased variant detection as optimal approach across applications.

Dr. Roschewski emphasizes that any blood test exceeds no testing, with most assays performing well at therapy initiation due to abundant ctDNA. End-of-therapy single time-point assessment requires highest analytical sensitivity, where phased variant approaches excel by detecting multiple abnormalities on identical cell-free DNA molecules. Statistical probability of noise generating multiple concurrent abnormalities remains extremely low, enabling deeper sequencing and enhanced detection capabilities.

Technical sensitivity requirements become complex when limited DNA quantities challenge claimed sensitivity levels (one-in-a-million detection requires million cellular equivalents in reactions). Phased variant detection helps overcome these limitations. Academic validation from investigators like Dan Hodson's group, developing independent phased variant approaches with similar results, provides company-agnostic scientific principles supporting broader technology adoption and marketplace development for clinical decision support scaling.